Search
Crisugabalin
go.drugbank.com/drugs/DB19300InvestigationalCrisugabalin is under investigation in clinical trial NCT06490484 (Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to
BMS-564929
go.drugbank.com/drugs/DB07286ExperimentalBMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). … So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
TBX-3400
go.drugbank.com/drugs/DB17370InvestigationalTBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.
Tovinontrine
go.drugbank.com/drugs/DB16193InvestigationalTovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With Sickle Cell Disease). … Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor.
Synonyms: 6-((3S,4S)-4-METHYL-1-(2-PYRIMIDINYLMETHYL)-3-PYRROLIDINYL)-3-(TETRAHYDRO-2H-PYRAN-4-YL)IMIDAZO(1,5-A)PYRAZIN-8(7H)-ONE, 6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-oneCaramiphen
go.drugbank.com/drugs/DB11504ExperimentalVet approvedAdditionally, it is used, in combination with [phenylpropanolamine], as a cough suppressant and nasal decongestant for the symptomatic treatment of seasonal respiratory conditions. … Caramiphen is a cholinergic antagonist used in Parkinson's disease.
SAR-125844
go.drugbank.com/drugs/DB15382InvestigationalSAR-125844 is under investigation in clinical trial NCT01391533 (Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors).
Birtamimab
go.drugbank.com/drugs/DB16414InvestigationalBirtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
ENTR-601-44
go.drugbank.com/drugs/DB17836InvestigationalENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]
PAS-004
go.drugbank.com/drugs/DB18611InvestigationalPAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Cardiopet
go.drugbank.com/drugs/DB18913InvestigationalCardiopet is under investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects).